Importantly, the reduction of tumor growth in the TRF group being abrogated by artificial insulin augmentation by insulin pump, suggests that TRF corrected obesity-induced hyperinsulinemia, and that this insulin-lowering effect was the mechanism by which tumor growth was inhibited in these postmenopausal breast cancer models. The gene discussed is INS; the disease is obesity disorder.